Could a common heart pill boost chemo against tough ovarian cancer?
NCT ID NCT07265739
Summary
This study is testing if adding losartan, a common blood pressure medication, to standard weekly paclitaxel chemotherapy can better control ovarian cancer that has stopped responding to platinum drugs. It will involve about 27 patients with this advanced, treatment-resistant form of the disease. The main goal is to see if the drug combination shrinks tumors and delays cancer growth, not to provide a permanent cure requiring no further medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.